A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

समान संसाधन

• A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
  द्वारा: Leijen, S, और अन्य
  प्रकाशित: (2011)
• DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
  द्वारा: Gupta, A, और अन्य
  प्रकाशित: (2013)
• AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study
  द्वारा: Dummer, R, और अन्य
  प्रकाशित: (2008)
• MEK1/2 blockade by AZD6244 (ARRY-142886) inhibits tumor growth and progression in an orthotopic human lung adenocarcinoma model with enhanced efficacy when combined with cediranib
  द्वारा: Takahashi, O, और अन्य
  प्रकाशित: (2009)
• Author Correction: Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer
  द्वारा: Jin-Hang Gao, और अन्य
  प्रकाशित: (2022-03-01)